Sirolimus and Hepatitis C following Liver Transplantation

Primary objectives: We believe that patients who have had a liver transplant and are infected with Hepatitis C will develop less scarring (fibrosis) in their transplant liver if their anti-rejection (immunosuppressant)medication is switched from a calcineurin inhibitor (current standard therapy) to Sirolimus. This trial will test this hypothesis. Primary endpoints: The primary endpoint is change in fibrosis stage over the study period.